Success Story: NIW Approved without RFE! We Helped a Theoretical and Computational Chemistry Expert Achieve Success
Client’s Testimonial:
"Thank you so much for your help throughout the application process."
On April 16th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Theoretical and Computational Chemistry (Approval Notice).
General Field: Theoretical and Computational Chemistry
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Egypt
State of Residence at the Time of Filing: Texas
Approval Notice Date: April 16th, 2026
Processing Time: 13 months, 5 days
Case Summary:
This approval reflects our firm's dedication to crafting well-supported, strategically compelling petitions for high-achieving researchers worldwide. We are pleased to share the success of an EB-2 NIW (National Interest Waiver) petition for a postdoctoral researcher in theoretical and computational chemistry from Egypt. Holding a Ph.D. in theoretical and computational chemistry, this researcher secured approval by demonstrating that their work carries both substantial merit and national importance to the United States.
Our firm successfully argued that contributions to cancer immunotherapy drug discovery, optogenetic protein modeling, and viral inhibitor development directly support critical national priorities in precision medicine, public health, and U.S. technological leadership in biotechnology and advanced computing.
Research Focus and National Importance
The proposed endeavor focuses on developing and applying computational and theoretical approaches alongside machine learning techniques to investigate proteins utilized as optogenetic switches, identify novel drug candidates, and explore the mechanisms and dynamics of proteins involved in various diseases. The research spans three key areas: identifying novel anticancer drugs and nanocarriers through computer-aided drug design, uncovering the structural mechanisms of a key model protein used in optogenetics, and investigating peptidomimetics as potential inhibitors of viral spike proteins.
This work holds clear national importance. Cancer and infectious diseases continue to pose urgent public health challenges in the United States, and the need for innovative drug candidates and improved treatment mechanisms has never been greater. This research directly addresses these challenges, while also advancing biotechnology, artificial intelligence, and advanced computing, areas recognized as critical to U.S. technological leadership, security, and long-term competitiveness.
Demonstrating Influence Through Research Impact
To demonstrate that this researcher is well-positioned to advance the proposed endeavor, our firm presented a strong and documented record of scholarly achievement. The portfolio includes 8 peer-reviewed journal articles (5 of them first-authored) and 5 abstracts (3 of them first-authored), published in highly ranked journals in the field. The work has been cited 47 times.
Beyond publications, this researcher has also been regularly invited to conduct peer review for a leading multidisciplinary journal and has completed at least 2 reviews to date, a reflection of the scientific community's recognition as a trusted expert in the field. The research has further received competitive funding from the National Institute of General Medical Sciences (NIGMS) and the National Institutes of Health (NIH), serving as meaningful external validation of the work's significance and its direct alignment with U.S. national health priorities.
The petition received 4 recommendations from experts. One expert has noted that:
"It is also pertinent to mention that [Client]'s work stimulates economic growth by fostering biotech innovation, creating jobs, and supporting national and international efforts to improve quality of life, thus making a profound impact in theoretical and computational chemistry."
The Result
With our firm's strategic preparation and careful framing of the petition, approval was granted in 13 months without RFE. This outcome reflects both the strength of the contributions presented and our team's expertise in showcasing complex scientific work in the most compelling light. We are proud to have supported this dedicated researcher and extend our sincere best wishes for continued success in advancing precision medicine and public health in the United States.